Molecular Partners AG ADR Total Liabilities
Molecular Partners AG ADR total liabilities. Based on the latest financial reports, Molecular Partners AG ADR (MOLN) has total liabilities worth $17.09 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MOLN financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Molecular Partners AG ADR (2013–2025)
Total liabilities of Molecular Partners AG ADR from 2013 to 2025. This chart illustrates how Molecular Partners AG ADR's total liabilities have evolved over time, based on quarterly financial data.
Molecular Partners AG ADR Competitors by Total Liabilities
The table below lists competitors of Molecular Partners AG ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Exsitec Holding AB
ST:EXS
|
Sweden | Skr877.81 Million |
|
AB Klaipedos nafta
F:XIC
|
Germany | €382.37 Million |
|
Estika Tata Tiara Tbk PT
JK:BEEF
|
Indonesia | Rp1.79 Trillion |
|
Manaksia Coated Metals & Industries Limited
NSE:MANAKCOAT
|
India | Rs4.06 Billion |
|
CJ Freshway Corporation
KQ:051500
|
Korea | ₩1.16 Trillion |
|
Amber International Holding Limited
NASDAQ:AMBR
|
USA | $195.23 Million |
|
Altin Yunus Cesme Turistik Tesisler AS
IS:AYCES
|
Turkey | TL1.52 Billion |
|
Maeil Dairies Co. Ltd
KQ:267980
|
Korea | ₩434.83 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Molecular Partners AG ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Molecular Partners AG ADR balance sheet assets.
Liquidity & Leverage Metrics
Molecular Partners AG ADR Total Liabilities Ratios Explained
Molecular Partners AG ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Molecular Partners AG ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Molecular Partners AG ADR (2013–2025)
The table below shows the annual total liabilities of Molecular Partners AG ADR from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $21.77 Million | +28.90% |
| 2024-12-31 | $16.89 Million | -22.95% |
| 2023-12-31 | $21.92 Million | -19.08% |
| 2022-12-31 | $27.09 Million | -58.56% |
| 2021-12-31 | $65.38 Million | -18.61% |
| 2020-12-31 | $80.33 Million | +58.13% |
| 2019-12-31 | $50.80 Million | -19.95% |
| 2018-12-31 | $63.45 Million | +129.12% |
| 2017-12-31 | $27.69 Million | -42.67% |
| 2016-12-31 | $48.30 Million | -28.55% |
| 2015-12-31 | $67.60 Million | +48.44% |
| 2014-12-31 | $45.54 Million | -26.31% |
| 2013-12-31 | $61.80 Million | -- |
About Molecular Partners AG ADR
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more